Advertisement ยท 728 ร— 90

Posts by Leukaemia Research Cytogenomics Group (LRCG)

As an invited speaker at the 2026 ๐Š๐จ๐ซ๐ž๐š๐ง ๐’๐จ๐œ๐ข๐ž๐ญ๐ฒ ๐จ๐Ÿ ๐‡๐ž๐ฆ๐š๐ญ๐จ๐ฅ๐จ๐ ๐ฒ ๐ˆ๐ง๐ญ๐ž๐ซ๐ง๐š๐ญ๐ข๐จ๐ง๐š๐ฅ ๐‚๐จ๐ง๐Ÿ๐ž๐ซ๐ž๐ง๐œ๐ž (๐ˆ๐‚๐Š๐’๐‡2026), ๐๐ซ๐จ๐Ÿ. Anthony Moorman shared insights on the "๐‘ฐ๐’๐’•๐’†๐’ˆ๐’“๐’‚๐’•๐’Š๐’๐’ ๐’๐’‡ ๐‘ด๐‘น๐‘ซ ๐’‚๐’๐’… ๐‘ฎ๐’†๐’๐’†๐’•๐’Š๐’„๐’” ๐’‚๐’” ๐’‚ ๐‘ป๐’‰๐’†๐’“๐’‚๐’‘๐’†๐’–๐’•๐’Š๐’„ ๐‘ฎ๐’–๐’Š๐’…๐’†๐’‘๐’๐’”๐’• ๐’Š๐’ ๐‘จ๐‘ณ๐‘ณ".๐Ÿงฌ The presentation focused on a critical shift in precision medicine: ๐Ÿฉธ๐๐ซ๐ž๐œ๐ข๐ฌ๐ข๐จ๐ง ๐’๐ญ๐ซ๐š๐ญ๐ข๐Ÿ๐ข๐œ๐š๐ญ๐ข๐จ๐ง: Moving beyond a "one-size-fits-all" approach by using subtype-specific Minimal Residual Disease (MRD) thresholds to guide therapy. ๐Ÿฉธ๐‘๐ž๐๐ฎ๐œ๐ข๐ง๐  ๐“๐จ๐ฑ๐ข๐œ๐ข๐ญ๐ฒ: Shifting the focus toward identifying patients who can be cured with less intensive chemotherapy. ๐Ÿฉธ๐…๐ฎ๐ญ๐ฎ๐ซ๐ž-๐๐ซ๐จ๐จ๐Ÿ๐ข๐ง๐ : Designing flexible risk algorithms that incorporate novel therapies like immunotherapy. By combining genomic data with treatment response, we are moving closer to a future where therapy is perfectly tailored to every patient.๐Ÿฅ

As an invited speaker at the 2026 ๐Š๐จ๐ซ๐ž๐š๐ง ๐’๐จ๐œ๐ข๐ž๐ญ๐ฒ ๐จ๐Ÿ ๐‡๐ž๐ฆ๐š๐ญ๐จ๐ฅ๐จ๐ ๐ฒ ๐ˆ๐ง๐ญ๐ž๐ซ๐ง๐š๐ญ๐ข๐จ๐ง๐š๐ฅ ๐‚๐จ๐ง๐Ÿ๐ž๐ซ๐ž๐ง๐œ๐ž (๐ˆ๐‚๐Š๐’๐‡2026), ๐๐ซ๐จ๐Ÿ. Anthony Moorman shared insights on the "๐‘ฐ๐’๐’•๐’†๐’ˆ๐’“๐’‚๐’•๐’Š๐’๐’ ๐’๐’‡ ๐‘ด๐‘น๐‘ซ ๐’‚๐’๐’… ๐‘ฎ๐’†๐’๐’†๐’•๐’Š๐’„๐’” ๐’‚๐’” ๐’‚ ๐‘ป๐’‰๐’†๐’“๐’‚๐’‘๐’†๐’–๐’•๐’Š๐’„ ๐‘ฎ๐’–๐’Š๐’…๐’†๐’‘๐’๐’”๐’• ๐’Š๐’ ๐‘จ๐‘ณ๐‘ณ".๐Ÿงฌ The presentation focused on a critical shift in precision medicine: ๐Ÿฉธ๐๐ซ๐ž๐œ๐ข๐ฌ๐ข๐จ๐ง ๐’๐ญ๐ซ๐š๐ญ๐ข๐Ÿ๐ข๐œ๐š๐ญ๐ข๐จ๐ง: Moving beyond a "one-size-fits-all" approach by using subtype-specific Minimal Residual Disease (MRD) thresholds to guide therapy. ๐Ÿฉธ๐‘๐ž๐๐ฎ๐œ๐ข๐ง๐  ๐“๐จ๐ฑ๐ข๐œ๐ข๐ญ๐ฒ: Shifting the focus toward identifying patients who can be cured with less intensive chemotherapy. ๐Ÿฉธ๐…๐ฎ๐ญ๐ฎ๐ซ๐ž-๐๐ซ๐จ๐จ๐Ÿ๐ข๐ง๐ : Designing flexible risk algorithms that incorporate novel therapies like immunotherapy. By combining genomic data with treatment response, we are moving closer to a future where therapy is perfectly tailored to every patient.๐Ÿฅ

At #๐ˆ๐‚๐Š๐’๐‡2026 in Seoul!๐Ÿฉธ

@avmoorman.bsky.social is presenting on integrating Genetics & MRD in Acute Lymphoblastic Leukaemia๐Ÿงฌ

๐ŸŽฏ Goal: Subtype-specific MRD thresholds to reduce over-treatment.
๐Ÿš€ Future: Flexible risk algorithms to support novel therapies.

#Leukaemia #PrecisionMedicine #Hematology

3 weeks ago 2 0 0 0
Turki, A.T., Fan, Y., Hernรกndez-Sรกnchez, A. et al. International testing and refinement of AI algorithms predicting acute leukemia subtypes from routine laboratory data. Nat Commun 17, 2649 (2026). https://doi.org/10.1038/s41467-026-70584-z

Turki, A.T., Fan, Y., Hernรกndez-Sรกnchez, A. et al. International testing and refinement of AI algorithms predicting acute leukemia subtypes from routine laboratory data. Nat Commun 17, 2649 (2026). https://doi.org/10.1038/s41467-026-70584-z

Proud to see @lrcg.bsky.social contribute to this global study in @nature.com(๐˜•๐˜ข๐˜ต. ๐˜Š๐˜ฐ๐˜ฎ๐˜ฎ๐˜ถ๐˜ฏ). We shared data to help refine AI that predicts leukemia subtypes from routine lab results, aiming to close global health diagnostic gaps๐Ÿฉธ๐ŸŒ

Read: doi.org/10.1038/s414...

#Leukemia #AI #NewcastleUni

3 weeks ago 1 0 0 0
Prof. Anthony Moorman presenting at the CCLG Annual Conference in Manchester, discussing how the VIVO Biobank and research from the Leukaemia Research Cytogenetics Group support advances in acute leukaemia research.

Prof. Anthony Moorman presenting at the CCLG Annual Conference in Manchester, discussing how the VIVO Biobank and research from the Leukaemia Research Cytogenetics Group support advances in acute leukaemia research.

Prof. Anthony Moorman presenting at the CCLG Annual Conference in Manchester, discussing how the VIVO Biobank and research from the Leukaemia Research Cytogenetics Group support advances in acute leukaemia research.

Prof. Anthony Moorman presenting at the CCLG Annual Conference in Manchester, discussing how the VIVO Biobank and research from the Leukaemia Research Cytogenetics Group support advances in acute leukaemia research.

Prof. Anthony Moorman presenting at the CCLG Annual Conference in Manchester, discussing how the VIVO Biobank and research from the Leukaemia Research Cytogenetics Group support advances in acute leukaemia research.

Prof. Anthony Moorman presenting at the CCLG Annual Conference in Manchester, discussing how the VIVO Biobank and research from the Leukaemia Research Cytogenetics Group support advances in acute leukaemia research.

Great to be at the Annual Conference of @cclguk.bsky.social in Manchester.

Prof. @avmoorman.bsky.social shared how the VIVO Biobank supports acute leukaemia research, highlighting key research from @lrcg.bsky.social, including the UKALL CNA profile in the ALLTogether trial.๐Ÿงฌ๐Ÿค

1 month ago 3 3 0 0
The talk focused on risk stratification in ๐‘ฉ-๐’„๐’†๐’๐’ ๐‘จ๐’„๐’–๐’•๐’† ๐‘ณ๐’š๐’Ž๐’‘๐’‰๐’๐’ƒ๐’๐’‚๐’”๐’•๐’Š๐’„ ๐‘ณ๐’†๐’–๐’Œ๐’‚๐’†๐’Ž๐’Š๐’‚ (๐‘ฉ-๐‘จ๐‘ณ๐‘ณ), emphasizing the role of cytogenetic approaches in identifying patient risk profiles and guiding treatment strategies๐Ÿ”ฌ๐Ÿ“Š.

The talk focused on risk stratification in ๐‘ฉ-๐’„๐’†๐’๐’ ๐‘จ๐’„๐’–๐’•๐’† ๐‘ณ๐’š๐’Ž๐’‘๐’‰๐’๐’ƒ๐’๐’‚๐’”๐’•๐’Š๐’„ ๐‘ณ๐’†๐’–๐’Œ๐’‚๐’†๐’Ž๐’Š๐’‚ (๐‘ฉ-๐‘จ๐‘ณ๐‘ณ), emphasizing the role of cytogenetic approaches in identifying patient risk profiles and guiding treatment strategies๐Ÿ”ฌ๐Ÿ“Š.

The talk focused on risk stratification in ๐‘ฉ-๐’„๐’†๐’๐’ ๐‘จ๐’„๐’–๐’•๐’† ๐‘ณ๐’š๐’Ž๐’‘๐’‰๐’๐’ƒ๐’๐’‚๐’”๐’•๐’Š๐’„ ๐‘ณ๐’†๐’–๐’Œ๐’‚๐’†๐’Ž๐’Š๐’‚ (๐‘ฉ-๐‘จ๐‘ณ๐‘ณ), emphasizing the role of cytogenetic approaches in identifying patient risk profiles and guiding treatment strategies๐Ÿ”ฌ๐Ÿ“Š.

The talk focused on risk stratification in ๐‘ฉ-๐’„๐’†๐’๐’ ๐‘จ๐’„๐’–๐’•๐’† ๐‘ณ๐’š๐’Ž๐’‘๐’‰๐’๐’ƒ๐’๐’‚๐’”๐’•๐’Š๐’„ ๐‘ณ๐’†๐’–๐’Œ๐’‚๐’†๐’Ž๐’Š๐’‚ (๐‘ฉ-๐‘จ๐‘ณ๐‘ณ), emphasizing the role of cytogenetic approaches in identifying patient risk profiles and guiding treatment strategies๐Ÿ”ฌ๐Ÿ“Š.

๐‘ฏ๐’Š๐’ˆ๐’‰๐’๐’Š๐’ˆ๐’‰๐’•๐’Š๐’๐’ˆ ๐‘ฉ-๐’„๐’†๐’๐’ ๐‘จ๐’„๐’–๐’•๐’† ๐‘ณ๐’š๐’Ž๐’‘๐’‰๐’๐’ƒ๐’๐’‚๐’”๐’•๐’Š๐’„ ๐‘ณ๐’†๐’–๐’Œ๐’‚๐’†๐’Ž๐’Š๐’‚ (๐‘ฉ-๐‘จ๐‘ณ๐‘ณ) ๐’“๐’†๐’”๐’†๐’‚๐’“๐’„๐’‰๐Ÿงฌ

Our group lead @avmoorman.bsky.social presented on risk stratification in B-ALL at the International ALL Assembly, sponsored by @amgen.bsky.social. Great opportunity to share our work with the international research community.

1 month ago 1 2 0 0
Post image

Excited to share our evaluation of the TALLSorts classifier!๐Ÿงฌ

Our research letter validates its utility against standard DNA methods for paediatric T-ALL, demonstrating high concordanceโœ…

Published now in British Journal of Haematology @wiley.com.
Read here: onlinelibrary.wiley.com/doi/10.1111/...

4 months ago 4 0 0 1
Preview
Search for Postgraduate Scholarships and Other Funding Search scholarships and funding for postgraduate study at Newcastle University. Find financial support tailored to your course and eligibility.

Sharing a great ๐๐ก๐ƒ ๐’๐ญ๐ฎ๐๐ž๐ง๐ญ๐ฌ๐ก๐ข๐ฉ opportunity in ๐๐ข๐จ๐ฌ๐ž๐ง๐ฌ๐จ๐ซ ๐“๐ž๐œ๐ก๐ง๐จ๐ฅ๐จ๐ ๐ฒ ๐Ÿ๐จ๐ซ ๐‚๐š๐ง๐œ๐ž๐ซ ๐Œ๐จ๐ง๐ข๐ญ๐จ๐ซ๐ข๐ง๐ . This multidisciplinary project focuses on developing next-generation biosensors for cancer monitoring and offers full funding for up to four years.

Click for more information: www.ncl.ac.uk/postgraduate...

4 months ago 1 0 0 1
Post image

Weโ€™re proud to see our Prof Christine Harrison featured speaking with His Royal Highness The Duke of Kent during one of his visits to @newcastleuni.bsky.social. We join @bloodcanceruk.bsky.social in wishing His Royal Highness a very happy 90th birthday ๐ŸŽ‰๐ŸŽ‚ and thanking him for his support.

5 months ago 3 1 0 0
Advertisement
Post image

Last month in Madrid, the ALLTogether1 trial brought Europeโ€™s teams roundtable. @avmoorman.bsky.social and other LRCG members shared genetics work to sort risk better and tailor treatment in ALL. Days like this remind us: good collaboration turns into patient impact. @newcastleuni.bsky.social

5 months ago 4 0 0 0
Preview
Lad diagnosed with cancer at 14 achieves dream of becoming doctor Cramlington-born Dan Mattison has become a doctor - fulfilling an ambition he has had since a teenage cancer diagnosis

From the North East: a cancer survivor who became a doctor - proof that resilience + research change lives. With CRUKโ€™s ยฃ4.1m boost to @newcastleuni.bsky.social, LRCG is excited to turn hope into outcomes. To the individual: your courage lifts us all. Read at www.chroniclelive.co.uk/news/north-e...

5 months ago 2 0 0 0
Post image

BIOINFORM (ยฃ2.7m @crukpolicy.bsky.social project) will: build CRISTAL (shared clinical/genomic data portal), develop AI risk tools to guide therapy, study new genetic changes in ALL, and map the genomics of childhood AML โ€” so each patient gets the most effective, least toxic treatment.

5 months ago 2 0 0 0
Post image

Exciting milestone as we held BIOINFORM project kick-off at @newcastleuni.bsky.social, funded by @crukpolicy.bsky.social. The day began with presentations tracing the history of LRCG and introducing the different work packages that will drive the BIOINFORM project forward.
@avmoorman.bsky.social

5 months ago 2 1 0 1